Compare AbbVie Inc (ABBV) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Atomera Incorporated — how do they compare? AbbVie Inc trades at $254.16 (market cap $449.91B), while Atomera Incorporated trades at $6.75 (market cap $284.76M). The key difference: AbbVie Inc is far larger — about 1580× Atomera Incorporated's market cap, and AbbVie Inc pays a 2.72% dividend while Atomera Incorporated pays none. Which is the better fit depends on your goals.
| ABBV | ATOM | |
|---|---|---|
Market Cap | $449.91B | $284.76M |
Sector | Health | Technology |
52-Week High | $261.07 | $12.11 |
52-Week Low | $184.85 | $1.99 |
Enterprise Value | $513.38B | $244.97M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ATOM trades at $7.355, down 0.74% with bearish technical signals. The company shows severe financial distress with negative gross margins of -520.83% and net losses of -$20.17 million in 2025. Recent earnings misses and negative cash flow highlight operational challenges despite 100% analyst buy ratings. Technical indicators show bearish momentum with support at $7 and resistance at $8.
The outlook remains highly speculative given extreme financial losses and negative cash flow. Investment opportunity hinges on successful commercialization of GaN semiconductor technology, while risks include continued cash burn and failure to achieve revenue growth. The stock represents a high-risk bet on unproven technology execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
